Comment on “Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy”

Lignende værker

• Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study
  af: Ahern, Thomas P., et al.
  Udgivet: (2016)
• No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications
  af: Ahern, Thomas P., et al.
  Udgivet: (2009)
• Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen
  af: Lash, Timothy L., et al.
  Udgivet: (2010)
• Functional polymorphisms in UDP-glucuronosyltransferases and recurrence in tamoxifen-treated breast cancer survivors
  af: Ahern, Thomas P., et al.
  Udgivet: (2011)
• CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
  af: Lash, Timothy L., et al.
  Udgivet: (2011)